Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.51 |
| ▸ | HTR2B | P41595 | 9/20 | 0.51 |
| ▸ | HTR6 | P50406 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330336 | 0.93 | PNMT (0.48) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL6166953 | 0.81 | HTR6 (0.63) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL6338171 | 0.76 | HTR6 (0.54) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL6332908 | 0.76 | HTR6 (0.64) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL6167732 | 0.76 | HTR6 (0.65) | HTR2CHTR2BHTR6CYP3A4 | |
| Hydrochloric Acid SCHEMBL6330320 | 0.75 | HTR6 (0.64) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL6332952 | 0.74 | HTR6 (0.55) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL22408161 | 0.74 | HTR6 (0.52) | HTR6HTR2A | |
| SCHEMBL6166989 | 0.73 | HTR6 (0.56) | HTR2CHTR2BHTR6CYP3A4 | |
| SCHEMBL6331245 | 0.70 | PNMT (0.51) | HTR2CHTR2BHTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392316-B1 | BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM PLC (GB) | 2005-04-20 | — | — | EP | claimed |
| US-20040192671-A1 | Benzo[d]azepine derivatives as 5-ht6 receptor anatagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-30 | — | — | US | claimed |
| EP-1392316-A1 | BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | claimed |
| WO-2002089811-A1 | BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | claimed |
| EP-1392316-B1 | BENZO[D]AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM PLC (GB) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192671-A1 | Benzo[d]azepine derivatives as 5-ht6 receptor anatagonists | HTR6, HTR5A, HTR1A | HTR2C 7/4885HTR2B 14/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.